

NOF CORPORATION

DDS DEVELOPMENT DIVISION

YEBISU GARDEN PLACE TOWER

20-3, EBISU 4-CHOME, SHIBUYA-KU, TOKYO 150-6019 JAPAN

TEL. +81-3-5424-6741 FAX. GIII +81-3-5424-6769

<http://www.nof.co.jp/dds> E-mail: ddsinfo@nof.co.jp



August 7th, 2012

NOF partners with AMBRX to manufacture and supply AMBRX Acetylene-, Azide-PEG (Polyethyleneglycol) derivatives..

NOF CORPORATION announced that NOF entered into a non-exclusive license agreement with Ambrx, Inc to manufacture and sell Ambrx patented Acetylene and Azide PEG for research purpose only (reagent to clinical stage). The financial terms of the license are not disclosed.

The agreement enables NOF to supply, on a global basis, Ambrx's original PEG reagents that are useful for protein conjugations, including "click chemistry". These PEGs can be manufactured by NOF under cGMP in our state of the art facility.

Further, NOF and Ambrx will work together to expand their line-up of activated PEG products using Ambrx proprietary technology. These novel products have the potential to bring new functionality and utility to protein conjugates. NOF will launch these new products in our catalog and promote them to pharmaceutical companies around the world.

About NOF CORPORATION

As an integrated chemical manufacturing featuring diverse activities from "Biosphere to Outer Space", NOF CORPORATION is a specialty fine chemical company and widely known as Drug Delivery System (DDS) products supplier such as Activated PEG, phospholipids, highly purified Polysorbate 80 and other novel excipients for pharmaceutical fields. As the worldwide leader in DDS, NOF supplies these products to rapidly growing areas driven by technological innovation to antibody, protein, peptides, RNA/DNA, aptamer, oligonucleotides, enzyme and novel small molecules. For more information, please visit [www/nof.co.jp/dds](http://www.nof.co.jp/dds).

About AMBRX

Ambrx, Inc. is a clinical stage biopharmaceutical company using an expanded genetic code to create best-in-class biotherapeutics, including antibody drug conjugates and proteins with improved pharmacologic properties. The company is developing ARX201, a long-acting growth hormone that has successfully completed Phase 2b clinical trials. Ambrx has collaborations to discover and develop products incorporating Ambrx technology with several pharmaceutical companies. Ambrx is advancing a robust portfolio of product candidates that are optimized for efficacy, safety and ease of use in multiple therapeutic areas. For additional information, visit www.ambrx.com.